JOSHUA QUINONES: Open Payments
NPI 1649736646 · STOUGHTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,184 in 63 payments from 10 companies in 2025. Trend: 2023 $992 · 2024 $951 · 2025 $1,184
Food & beverage: $1,184
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $272 |
| Alkermes, Inc. | 14 | $218 |
| ABBVIE INC. | 11 | $178 |
| Otsuka America Pharmaceutical, Inc. | 5 | $135 |
| Neurocrine BioSciences, Inc. | 4 | $99 |
| Lundbeck LLC | 5 | $98 |
| Vanda Pharmaceuticals Inc. | 2 | $65 |
| Axsome Therapeutics, Inc. | 2 | $59 |
| E.R. Squibb & Sons, L.L.C. | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
Products named: CAPLYTA, REXULTI, ARISTADA, VRAYLAR, INGREZZA, FANAPT, Auvelity, VIVITROL.
Industry payments across MA — which companies pay providers there.
